Stocks | | |
Have we turned a corner? This inherently hopeful and largely rhetorical question has underscored a lot of the world's life these days. Has the coronavirus pandemic started retreating to the point where life looks like it once did and we can actually go back to work? Has the stock market stopped it... Read the Full Story |
|
From Our PartnersStock are dead (for now). Luckily we've discovered an alternative...
An investment that's nearly 10x more profitable than stocks, but yet has nothing to do with the stock market.
In fact, this under the radar market is responsible for the most profitable investment of all time! | | Click here for details >> |
|
Markets | | | As markets continue to rebound from one of the most vicious sell-offs in history, many investors are looking for quality stocks that are trading at significant discounts to where they were a month or two ago. While overall volatility is still elevated, there’s no doubt that attractive buying o... Read the Full Story |
|
Markets | | | Payment solutions provider Square (NYSE: SQ) shares took a heavy bearing during the coronavirus pandemic sinking to lows of $32.33 on March 18, 2020. This move was positively correlated to the S&P 500 (NYSEARCA: SPY) which collapsed over 35 percent in just under a month. Prior to this black swan... Read the Full Story |
|
Markets | | | It all depends on what market conditions are like, your personal trading strategy, and your comfort level. Financial markets are constantly evolving and incorporating new information into security prices. Read the Full Story |
|
Markets | | | A Preemptive Strike
When the market saw the black swan of coronavirus approaching it reacted in the only way it could. Instead of waiting for this thing to hit, waiting to see how bad it might be, the market started selling. The general thought went something like this “it’s better to b... Read the Full Story |
|
From Our PartnersEric Fry, one of America's top Investment Strategists, provides his latest report 5 Tech Stocks Set for 1,000% Gains after the Coronavirus Sell off. You can't afford to miss out on the once in a decade chance to buy after the recent 25% dip in the markets. Download this hot-off-the-presses research report now. | | It's yours FREE. |
|
The Early Bird Stock Of The Day Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. | | View Today's Stock Pick |
|
